
Rezolute Net Income | RZLT
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Rezolute
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.6 M | -74.4 M | -68.5 M | -51.8 M | -41.1 M | -20.9 M | -20.3 M | -30.4 M | -29.9 M | -20.3 M | -14.9 M | -11.4 M | -9.73 M | -6.73 M | -49.3 K | - | -301 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -49.3 K | -77.6 M | -29.9 M |
Quarterly Net Income Rezolute
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.5 M | -20.5 M | -16.2 M | -22.8 M | -18.2 M | -24.4 M | -18.9 M | -15.7 M | -15.4 M | -23 M | -17 M | -13.9 M | -14.5 M | -12.7 M | -15.7 M | -13.6 M | -9.83 M | -13.6 M | -11.2 M | -23.4 M | -7.84 M | -6.49 M | -3.7 M | -7.1 M | -3.62 M | -7.1 M | -3.62 M | -7.1 M | -3.62 M | -6.67 M | -5.08 M | -6.67 M | -3.37 M | -4.16 M | -3.36 M | -4.16 M | -3.37 M | -5.72 M | -6.68 M | -5.72 M | -6.68 M | -4.89 M | -3.82 M | -4.89 M | -3.29 M | -4.07 M | -3.29 M | -4.07 M | -3.29 M | -2.94 M | -2.21 M | -2.94 M | -2.21 M | -1.82 M | -820 K | -538 K | -820 K | -538 K | -631 K | -8 K | -177 K | -8 K | -7.39 K | -8 K | -7.39 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.39 K | -24.4 M | -7.66 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Denali Therapeutics
DNLI
|
-513 M | $ 18.41 | 2.25 % | $ 3.18 B | ||
|
Amarin Corporation plc
AMRN
|
-38.8 M | $ 11.25 | -0.18 % | $ 4.67 B | ||
|
ImmuCell Corporation
ICCC
|
-1.04 M | $ 11.2 | -1.15 % | $ 101 M | ||
|
Editas Medicine
EDIT
|
-160 M | $ 1.77 | -3.29 % | $ 157 M | ||
|
Agios Pharmaceuticals
AGIO
|
-413 M | $ 29.7 | -0.64 % | $ 1.72 B | ||
|
Pfizer
PFE
|
7.77 B | $ 28.06 | -1.46 % | $ 159 B | ||
|
NuCana plc
NCNA
|
-29.4 M | $ 0.82 | -7.71 % | $ 9.21 B | ||
|
Equillium
EQ
|
-22.4 M | $ 1.1 | -9.5 % | $ 63 M | ||
|
Black Diamond Therapeutics
BDTX
|
22.4 B | $ 1.43 | -1.04 % | $ 81.3 M | ||
|
Abeona Therapeutics
ABEO
|
-71.2 M | $ 2.73 | 4.81 % | $ 145 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
391 M | $ 18.0 | -1.77 % | $ 3.03 B | ||
|
Atossa Therapeutics
ATOS
|
-34.8 M | $ 1.8 | -5.26 % | $ 15.5 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
-2.4 M | - | -7.31 % | $ 49 M | ||
|
Pliant Therapeutics
PLRX
|
149 M | $ 0.66 | 0.38 % | $ 40.5 M | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
-84.3 M | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.33 | -1.48 % | $ 169 M | ||
|
Harmony Biosciences Holdings
HRMY
|
159 M | $ 33.1 | 0.29 % | $ 1.9 B | ||
|
Ardelyx
ARDX
|
-62 M | $ 3.15 | -1.1 % | $ 759 M | ||
|
Akebia Therapeutics
AKBA
|
-5.3 M | $ 0.41 | 2.22 % | $ 105 M | ||
|
Alector
ALEC
|
-143 M | $ 2.56 | 1.17 % | $ 264 M | ||
|
ALX Oncology Holdings
ALXO
|
-102 M | $ 0.97 | -3.11 % | $ 52 M | ||
|
Amneal Pharmaceuticals
AMRX
|
72.1 M | $ 21.81 | 3.27 % | $ 6.83 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.12 | 1.6 % | $ 789 M | ||
|
Agenus
AGEN
|
-3.08 M | $ 6.39 | 2.82 % | $ 190 M | ||
|
PolyPid Ltd.
PYPD
|
-34.2 M | $ 6.52 | -0.31 % | $ 107 M | ||
|
AbCellera Biologics
ABCL
|
-146 M | $ 11.0 | -0.32 % | $ 3.29 B | ||
|
Artelo Biosciences
ARTL
|
-12.9 M | $ 1.5 | -10.71 % | $ 284 K | ||
|
Immatics N.V.
IMTX
|
-196 M | $ 6.11 | -2.94 % | $ 748 M | ||
|
Aptevo Therapeutics
APVO
|
-26 M | $ 0.45 | -3.45 % | $ 142 K | ||
|
Aligos Therapeutics
ALGS
|
-24.2 M | $ 1.3 | -4.41 % | $ 12.9 M | ||
|
Aclaris Therapeutics
ACRS
|
-64.9 M | $ 3.48 | 2.81 % | $ 427 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 28.47 | -0.07 % | $ 4.32 B | ||
|
Cellectar Biosciences
CLRB
|
-21.8 M | $ 0.89 | -3.51 % | $ 2.32 M | ||
|
Larimar Therapeutics
LRMR
|
-166 M | $ 3.22 | 7.69 % | $ 268 M | ||
|
Biofrontera AG
BFRA
|
-13 M | - | -8.24 % | $ 105 M | ||
|
Pulmatrix
PULM
|
-1.17 M | $ 1.34 | -2.19 % | $ 4.89 B | ||
|
Intellia Therapeutics
NTLA
|
-413 M | $ 9.68 | -1.07 % | $ 1.05 B | ||
|
Pharming Group N.V.
PHAR
|
33 M | $ 12.48 | 3.51 % | $ 8.6 B | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
-37.3 M | - | -6.97 % | $ 657 M | ||
|
Capricor Therapeutics
CAPR
|
-105 M | $ 8.04 | -4.4 % | $ 374 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 29.66 | 1.91 % | $ 1.39 B | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
57.2 B | $ 14.98 | 1.28 % | $ 12.5 B | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
152 M | - | 1.68 % | $ 4.65 B | ||
|
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 945.14 | -1.32 % | $ 98.9 B | ||
|
Aquestive Therapeutics
AQST
|
-83.8 M | $ 3.78 | 2.16 % | $ 404 M | ||
|
Jaguar Health
JAGX
|
-54 K | $ 0.35 | -8.69 % | $ 816 K | ||
|
Arvinas
ARVN
|
-81 M | $ 6.77 | -0.73 % | $ 480 M | ||
|
Cerus Corporation
CERS
|
-15.6 M | $ 1.95 | 2.63 % | $ 372 M | ||
|
Beam Therapeutics
BEAM
|
-80 M | $ 21.03 | 1.82 % | $ 2.08 B | ||
|
Inhibrx
INBX
|
-241 M | $ 68.87 | -7.16 % | $ 3.25 B |